In IDHmt astrocytoma, T cell exclusion is typically accompanied by focal presence of GTCs, and even though the focal presence of GTCs is likely transient as evidenced by our analyses of consecutive resections, the early targeting of CD44+ GTCs or nearby SPP1+ TAMs holds potential therapeutic value to break immune tolerance in this disease. Here, SPP1 is linked to astrocytoma (excluding glioblastoma).